7 IAS officers to take charge of each Mumbai zone to fight Covid-19

Prisoners equally enjoy right to life as those outside: Bombay HC on Covid-19 spread in jail

33 test positive for Covid-19 in Mira-Bhayander, tally climbs to 235

Maharashtra home minister thanks cops for Covid-19 fight with logo tribute

51 new Covid +ve cases in Thane in 24 hours

Govt revises discharge policy for Covid patients

China conducts 1st Covid vaccine test on monkeys

'New drug combo shows promise against Covid'

The predictive power of the App highlights the potential utility of real-time symptom tracking

Even after more than six weeks of national lockdown, there is no sign of any flattening of the curve but instead the number of new novel coronavirus c

Interview with Mihai Gheorghiade, MD, author of Improving Postdischarge Outcomes in Patients Hospitalized for Acute Heart Failure Syndromes

Interview with Tarak K. Trivedi, BS, author of Hospitalizations and Mortality Associated With Norovirus Outbreaks in Nursing Homes, 2009-2010

Interview with Marianna K Baum, PhD, author of Effect of Micronutrient Supplementation on Disease Progression in Asymptomatic, Antiretroviral-Naive, HIV-Infected Adults in Botswana

Interview with Harsha Thirumurthy, PhD, author of Effect of Providing Conditional Economic Compensation on Uptake of Voluntary Medical Male Circumcision in Kenya: A Randomized Clinical Trial

Interview with Anthony S. Fauci, MD, author of Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Obstacles

Interview with Pascale Carayon, PhD, author of Improving the System to Support Clinician Well-being and Provide Better Patient Care

Interview with Maya M. Hammoud, MD, MBA, author of Improving the Residency Application and Selection Process: An Optional Early Result Acceptance Program

By mid-February 2020 there were 60,000 confirmed cases of COVID-19, the vast majority diagnosed in Hubei Province (including Wuhan city) in mainland China. China CDC Chief Epidemiologist Zunyou Wu, MD, PhD discusses the latest COVID-19 developments in the country with JAMA Editor in Chief Howard Bauchner, MD.

Coronavirus testing, mortality, vaccine development, containment vs mitigation, and more. JAMA Editor Howard Bauchner, MD, interviews US NIAID Director Anthony Fauci, MD, about the latest developments in SARS-CoV-2 science and global spread of infection.

JAMA Coronavirus Resource Page

Diagnostic testing, NSAIDs, ACE Inhibitors, antivirals, and more. Anthony Fauci, MD from NIAID discusses latest developments in the spread and clinical management of COVID-19 and the SARS-CoV-2 virus with JAMA Editor Howard Bauchner, MD.

JAMA Coronavirus Resource Center

The strategy for managing the COVID-19 pandemic has shifted from containment to mitigation. What does that mean for US hospitals and health systems? Kaiser Permanente Executive Vice President Stephen M. Parodi, MD, discusses telemedicine, protecting health care workers, equipment allocation planning, and more.

As COVID-19 spreads globally, populations who survive their illness will become immune. Mayo Vaccine Research Group Director Gregory Poland, MD, discusses antibody responses, duration of immunity, vaccine safety, and the prospects for using convalescent serum to passively immunize people unexposed to SARS-CoV-2.

Hospitals need ways to make rational, fair decisions about who gets ICU beds and ventilators if COVID-19 patients overwhelm capacity. Douglas B. White, MD, MAS, Director of the Program on Ethics and Decision Making in Critical Illness at the University of Pittsburgh, discusses a framework for those decisions and a guideline he helped develop for allocation of scarce resources in public health emergencies.

How does the current pandemic compare to historical infectious outbreaks and what can we expect in summer and fall of 2020? Nicholas Christakis, MD, PhD, MPH, director of the Human Nature Lab, Co-director of the Institute of Network Science, and Sterling Professor of Social and Natural Science at Yale University, discusses the epidemiology of COVID-19.

Noninvasive ventilation (NIV), working with dying patients’ families, use of experimental therapies, and more. JAMA Associate Editor Derek Angus, MD, MPH, Distinguished Professor and Chair of Critical Care Medicine at the University of Pittsburgh, provides a COVID-19 ICU management update.

Watch the recording of this livestream

Infectious epidemics have always driven change and triggered discrimination in human societies. Frank Snowden, DPhil, Professor Emeritus of History and History of Medicine at Yale University and author of Epidemics and Society: From the Black Death to the Present (Yale University Press, 2019), puts the COVID-19 pandemic in historical context.

Questions about testing, chloroquine toxicity, duration of immunity and reinfection, and what to expect next are gripping the US as the novel coronavirus spreads. JAMA Associate Editor Preeti Malani, MD, professor of medicine and Chief Health Officer at the University of Michigan, discusses recent developments in a live conversation with JAMA Editor in Chief Howard Bauchner. Recorded on April 6, 2020.

New York City coronavirus update from Mitchell Katz, MD, President and CEO of NYC Health + Hospitals, the largest municipal public health system in the United States. Recorded April 13, 2020.

Rochelle Walensky, MD, MPH, of Harvard University discusses public health strategies and policies for lifting shelter-in-place and quarantine and for returning the US to a new post-first-wave normal. Recorded Monday April 20, 2020.

Marc Lipsitch, DPhil, an infectious diseases epidemiologist developing biological and modeling approaches to pathogen transmission and outbreaks, discusses evolution of the COVID-19 pandemic in summer and fall 2020. Originally recorded April 22, 2020.

The US spends more on health care as a proportion of its GDP than any other nation. Will the COVID-19 pandemic reduce or accelerate that spending? Sherry Glied, PhD, Dean and Professor of Public Service at New York University, explains. Recorded Monday, April 27, 2020.

Read the article

The Potential Effects of Coronavirus on National Health Expenditures

Don Berwick, MD, MPP, of the Institute for Healthcare Improvement, discusses choices societies and the medical profession can make to improve health care and reduce inequities as we move out of the acute phase of the coronavirus pandemic.

Hayden Library - TL793.C377 2018

Barker Library - TL725.3.M2 A47 2019

Barker Library - TL698.A27 2019

Ithaca : Cornell University Press, 1998

London ; New York : Routledge, 2007

Rotch Library - DR557.O88 2016

Rotch Library - HT371.E85 2016

Rotch Library - NA9246.6.J4 A73 2015

Rotch Library - NA1502.K43 2016

Rotch Library - DR1667.T67 2017

Rotch Library - DT299.A5 C84 2006

Rotch Library - DS99.A56 A355 2019

With the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic, individuals with preexisting chronic health conditions such as hypertension, diabetes, and cardiovascular disease have been identified as particularly vulnerable. These patients are also more likely than the general population to be taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 gains entry into cells via binding to the angiotensin-converting enzyme 2 (ACE2) receptor, concerns have been raised that these therapies might facilitate the transmission of the virus or affect outcomes adversely. Given that ACEI and ARB therapies are known to provide benefit for the underlying conditions treated, stopping ACEI/ARB therapy carries risks. Moreover, local inactivation of the renin-angiotensin-aldosterone system may have protective effects against the development and progression of acute lung failure. In the absence of clinical evidence of benefit or risk of ACEIs/ARBs, current societal statements recommend against discontinuing these drugs other than for standard clinical indications. Robust clinical data are needed to clarify the effect of ACEIs/ARBs on SARS-CoV-2 infection.

This cohort study assesses the association between use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with the likelihood of testing positive for coronavirus disease 2019 (COVID-19).

The U.S. Department of Agriculture (USDA) is ensuring the safety and timely delivery of the U.S. food supply while protecting the health of USDA employees during this COVID-19 National Emergency. Yesterday, USDA Under Secretary for Marketing and Regulatory Programs Greg Ibach and USDA Deputy Under Secretary for Food Safety Dr. Mindy Brashears sent a letter to stakeholders reassuring them that APHIS, AMS, and FSIS are rising to meet the challenges associated with COVID-19.